Medicare advisory panel to hold meeting:
This article was originally published in Clinica
The Medicare coverage advisory committee's panel on laboratory and diagnostic services will convene next month to discuss whether the US federal health plan for the elderly and disabled should cover human tumour assay systems that detect resistance or sensitivity to chemotherapeutic agents. The Health Care Financing Administration (HCFA), which administers Medicare, currently considers such tests experimental and therefore declines to cover them. Three groups - including companies Oncotech of Irving, California and Rational Therapeutics of Long Beach, California - have asked HCFA to alter its coverage policy. The two-day event will take place on November 15 and 16 in Baltimore and will be the first public meeting of the laboratory panel.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.